AOD-9604 — a peptide studied for fat metabolism, body composition, and recovery support.
AOD-9604 is a synthetic fragment of human growth hormone, corresponding to the last 16 amino acids of the hormone's chain with a small structural modification. It was developed in the early 2000s as a candidate obesity therapy, designed around the observation that the fat-burning effects of growth hormone seem to be concentrated in this short tail region of the molecule — separate from the parts of the hormone that drive growth and insulin-related effects.
The appeal of AOD-9604 is the idea of isolating one specific action of growth hormone — the breakdown and reduced storage of fat — without the broader hormonal effects that come with full growth hormone use. Early clinical development through the company Metabolic advanced the compound into Phase IIa trials for obesity, and interest in it has since broadened to include metabolic support and, more recently, tissue recovery contexts.
It remains an investigational peptide, frequently discussed alongside other growth-hormone-related compounds like CJC-1295, ipamorelin, sermorelin, and tesamorelin in the emerging peptide-therapy literature.
No vendors tracked for AOD-9604 yet — check back soon.
AOD-9604 was specifically engineered to target the metabolic side of growth hormone activity. Growth hormone has long been known to promote lipolysis — the breakdown of stored fat into usable fatty acids — and to reduce the conversion of new calories into fat tissue. AOD-9604 was designed to retain these fat-related effects while leaving behind the growth-promoting and glucose-related actions that limit growth hormone's use as a weight-loss agent.
The compound entered clinical development as a potential obesity treatment, with Phase IIa trials underway by 2002 (1). The early interest centered on whether a small, targeted fragment could deliver the metabolic benefits of growth hormone in a cleaner, more controllable form than the full hormone itself. While AOD-9604 did not progress to approval as an obesity drug, it remains one of the more frequently studied growth-hormone-derived peptides and continues to appear in reviews of metabolic and performance-oriented compounds (3).
More recent reviews have placed AOD-9604 in a broader category of growth hormone secretagogues and growth-hormone-related peptides studied for their effects on tissue recovery. In this framing, AOD-9604 is grouped with ipamorelin, CJC-1295, tesamorelin, and sermorelin as compounds that may activate IGF-1 signaling and satellite cell repair — the pathway by which muscle and connective tissue rebuild after injury (4).
IGF-1, or insulin-like growth factor 1, is one of the main downstream messengers of growth hormone activity, and it plays a central role in tissue regeneration, protein synthesis, and the activation of satellite cells, which are the stem-cell-like repair cells embedded in muscle. By engaging this signaling axis, AOD-9604 has been discussed as a potential adjunct in musculoskeletal recovery contexts, though the orthopaedic literature is clear that preclinical signals have not yet been matched by rigorous clinical trials (3, 4). For now, its role in recovery remains a topic of active interest rather than established practice.
Because AOD-9604 is a fragment of human growth hormone, a natural question is whether it interferes with the tests used to detect growth hormone doping in sport. A 2013 analysis examined this directly and found that AOD-9604 does not influence the WADA human growth hormone isoform immunoassay (2) — the standard test used by anti-doping authorities to distinguish administered growth hormone from naturally produced hormone.
This is a technical but important point: it means AOD-9604 is distinguishable from growth hormone at the assay level, which has implications for how it's categorized in sport. AOD-9604 has nonetheless been discussed in sports medicine reviews as part of the broader landscape of unapproved peptides used by athletes and active patients (3), and competitive athletes should be aware that peptide regulations evolve and vary by governing body.
Reported side effects for AOD-9604 in the available research are minimal, and the compound was generally well tolerated in the clinical development work conducted during its evaluation as an obesity therapy (1, 3). Anecdotally, some users report mild injection-site reactions or transient fatigue, which typically resolve quickly.
The body of AOD-9604 evidence comes primarily from preclinical and laboratory work, with limited human clinical data so far. Long-term safety has not been formally characterized, and the orthopaedic and sports medicine literature notes that rigorous human safety data for this class of peptides remains scarce (3, 4). Competitive athletes should also be aware that peptide regulations in professional sport evolve over time and vary by governing body, even when a compound does not interfere with standard anti-doping assays (2).
All information on this site is for research and educational purposes only. The compounds discussed are not approved by the FDA and are not intended to diagnose, treat, cure, or prevent any disease.